← Browse by Condition
Medical Condition
relapsed or refractory multiple myeloma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1
NCT05927571 Phase 1
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Enrollment
120 pts
Location
Australia, Israel, S...
Sponsor
Genentech, Inc.
NCT05913804 Phase 1
Recruiting
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
Enrollment
12 pts
Location
China
Sponsor
Institute of Hematology & Bloo...